Strategic Insights requested from Leading Journals
This collection of papers commissioned by top pharmaceutical and healthcare journals, offering strategic insights into AI integration, innovation, and compliance.
Embedded Files
Drug Target Review · April 29, 2025
Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.
Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.
Drug Target Review · March 21, 2025
The report explores the increasing impact of large language models (LLMs) in enhancing research efficiency and improving decision-making. Featuring insights from leading AI experts, it provides a comprehensive look at how AI is revolutionising drug discovery – and the key challenges that are yet to be overcome.
The report explores the increasing impact of large language models (LLMs) in enhancing research efficiency and improving decision-making. Featuring insights from leading AI experts, it provides a comprehensive look at how AI is revolutionising drug discovery – and the key challenges that are yet to be overcome.
European Pharmaceutical Review · March 28, 2025
Artificial intelligence (AI) and Big Data are set to remain the most disruptive powers in the healthcare sector for the next two years, with Pharma executives prioritizing these innovations for the near future, according to GlobalData. This report delves into some of the major obstacles and the potential for AI in the pharmaceutical industry.
Artificial intelligence (AI) and Big Data are set to remain the most disruptive powers in the healthcare sector for the next two years, with Pharma executives prioritizing these innovations for the near future, according to GlobalData. This report delves into some of the major obstacles and the potential for AI in the pharmaceutical industry.
Journal of Diabetes, Science and Technology · 26 December 2024
PMCID: PMC11672366 PMID: 39726262AI in diabetes management offers advanced solutions but presents safety and compliance challenges. This article explores xAI’s role in ensuring transparency, security, and trust, analyzing technical and regulatory aspects. It proposes risk mitigation strategies and GRC guidelines to develop reliable, compliant AI solutions that enhance patient engagement and improve clinical outcomes.
PMCID: PMC11672366 PMID: 39726262AI in diabetes management offers advanced solutions but presents safety and compliance challenges. This article explores xAI’s role in ensuring transparency, security, and trust, analyzing technical and regulatory aspects. It proposes risk mitigation strategies and GRC guidelines to develop reliable, compliant AI solutions that enhance patient engagement and improve clinical outcomes.
Page updated
Google Sites
Report abuse